Decheng Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Decheng Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-92,700	Closed	-$4.32M	–	16
2025 Q4	$4.32M	Sell	92,700 -50,300	-35%	-$2.24M	0.58%	12
2025 Q3	$5.96M	Hold	143,000	–	–	1.04%	13
2025 Q2	$4.11M	Sell	143,000 -34,958	-20%	-$1.08M	1.04%	14
2025 Q1	$5.97M	Buy	177,958 +10,000	+6%	+$373K	1.67%	14
2024 Q4	$8.59M	Buy	167,958 +10,000	+6%	+$559K	1.84%	10
2024 Q3	$8.07M	Hold	157,958	–	–	1.91%	12
2024 Q2	$7.07M	Hold	157,958	–	–	2.17%	13
2024 Q1	$7.39M	Buy	+157,958	New	+$6.18M	0.99%	12

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Decheng Capital's CRNX Position: Q1 2026 in Review

Decheng Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 92,700 shares — an estimated $4.32M sold.

Decheng Capital first reported a position in CRNX in Q1 2024 and held it in 8 quarters. The position peaked at $8.59M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Decheng Capital reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Decheng Capital sold 92,700 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $4.32M.
Decheng Capital first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 8 quarters.
Decheng Capital's Crinetics Pharmaceuticals position peaked at $8.59M in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Decheng Capital's 13F filing for Q1 2026, filed 13 May 2026.